{"schema_version":"1","generated_at":"2026-11-10T17:03:34.791Z","data_as_of":null,"url":"https://www.findmykol.com/kol/claudia-tellez","json_url":"https://www.findmykol.com/kol/claudia-tellez/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"claudia-tellez","name":"Claudia Tellez","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Northwestern University","institution_url":"https://www.findmykol.com/institution/northwestern-university-feinberg-school-of-medicine","city":"Chicago","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1114916517","openalex":"A5063475642"},"summary":"Claudia Tellez is an Oncology physician affiliated with Northwestern University. OpenAlex indexes 23 publications with 640 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":23,"cited_by_count":640,"h_index":9,"latest_activity_year":2026,"emerging":true,"source":"works"},"trials":{"count":1,"shown":1,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00004897","title":"Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer","phase":"PHASE2","status":"TERMINATED","role":"Overall official","sponsor":"Northwestern University","source_url":"https://clinicaltrials.gov/study/NCT00004897","trial_url":"https://www.findmykol.com/trial/NCT00004897"}],"source":"trials"},"payments":{"company_count":7,"program_years":{"first":2021,"last":null},"rows_total":11,"shown":3,"withheld":8,"rows":[{"payer":"AstraZeneca Pharmaceuticals LP","program_year":2025,"amount_usd":43.25,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1114916517"},{"payer":"Pfizer","program_year":2024,"amount_usd":20000,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1114916517"},{"payer":"PFIZER INC.","program_year":2024,"amount_usd":68.45,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1114916517"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1114916517","source":"payments"},"prescribing":{"data_year":2024,"areas_total":6,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":46,"classes_total":6,"classes":[{"class":"HER2/neu Receptor Antagonist","setting":"administered","share_pct":41.5,"drugs":[{"name":"Fam-trastuzumab deruxtecan-nxki","share_pct":100}],"max_beneficiaries":15},{"class":"Estrogen Receptor Antagonist","setting":"administered","share_pct":2.4,"drugs":[{"name":"Fulvestrant","share_pct":100}],"max_beneficiaries":20}]},{"area":"Metabolism & gastrointestinal","share_pct":27.8,"classes_total":3,"classes":[{"class":"Other antiemetics","setting":"administered","share_pct":26,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":22},{"class":"Serotonin-3 Receptor Antagonist","setting":"administered","share_pct":1.8,"drugs":[{"name":"Palonosetron hcl","share_pct":100}],"max_beneficiaries":24}]},{"area":"Musculoskeletal","share_pct":23.7,"classes_total":1,"classes":[{"class":"RANK Ligand Inhibitor","setting":"administered","share_pct":23.7,"drugs":[{"name":"Denosumab","share_pct":100}],"max_beneficiaries":34}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":23,"shown":5,"withheld":18,"matched_by":"OpenAlex author record","recent":[{"title":"Abstract PS2-02-25: Centering the Patient Experience within TNBC Care and Fostering Equity in the Hispanic and Latina Populations","year":2026,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs25-ps2-02-25","status":"verified"},{"title":"Abstract 4708: FGFR gene amplification and response to HER2-directed therapy in patients with HER2+ metastatic breast cancer (MBC)","year":2025,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.am2025-4708","status":"verified"},{"title":"Abstract P5-03-06: Correlation of Mutational Changes in Circulating Tumor DNA with Clinical Outcomes in HER2 Positive Metastatic Breast Cancer","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs24-p5-03-06","status":"verified"},{"title":"FGFR gene amplification and response to HER2-targeted therapy in patients with HER2-expressing metastatic breast cancer","year":2025,"journal":"Research Square","source_url":"https://doi.org/10.21203/rs.3.rs-6641146/v1","status":"verified"},{"title":"Abstract P2-07-16: Rising ESR1 Mutations in Circulating Tumor DNA (ctDNA) Mediate Endocrine Therapy (ET) Resistance to Everolimus and ET but Retain Sensitivity to Fulvestrant in HR+/HER2- Metastatic Breast Cancer (MBC)","year":2025,"journal":"Clinical Cancer Research","source_url":"https://doi.org/10.1158/1557-3265.sabcs24-p2-07-16","status":"verified"}],"source":"works"},"contact":{"address_1":"980 N MICHIGAN AVENUE SUITE 1086","city":"Chicago","state":"IL","zip":"60611","phone":"312-312-3650","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1114916517","source":"identity"},"similar":[{"name":"Rosalind Ramsey-Goldman","slug":"rosalind-ramsey-goldman","institution":"Northwestern University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/rosalind-ramsey-goldman","json_url":"https://www.findmykol.com/kol/rosalind-ramsey-goldman/profile.json"},{"name":"Timothy Kuzel","slug":"timothy-kuzel","institution":"Northwestern University","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/timothy-kuzel","json_url":"https://www.findmykol.com/kol/timothy-kuzel/profile.json"},{"name":"Rowland Chang","slug":"rowland-chang","institution":"Northwestern University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/rowland-chang","json_url":"https://www.findmykol.com/kol/rowland-chang/profile.json"},{"name":"Paul Cremer","slug":"paul-cremer","institution":"Northwestern University","specialty":"Cardiovascular Disease","url":"https://www.findmykol.com/kol/paul-cremer","json_url":"https://www.findmykol.com/kol/paul-cremer/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":8,"publications":18}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-02-24","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}